Chemosensitivity Assay

OTHER2 trials

Sponsors

University of Washington

Conditions

Recurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Plasma Cell MyelomaRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Plasma Cell Myeloma

Phase 2

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

TerminatedNCT03256045

University of WashingtonRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2018-02-08End: 2021-02-05Updated: 2022-05-09

Unknown Phase

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

CompletedNCT02551718

University of WashingtonRecurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia +3

Start: 2015-09-11End: 2021-05-13Updated: 2022-06-30

Related Papers

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Blood2022-11-153 citations

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood2019-11-132 citations

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Blood2019-11-132 citations

A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood2016-12-02